Alzheimer's Disease costs U.S. society over $100 billion annually, making it the 3rd most costly disease after heart disease and cancer.
Alzheimer's Disease affects 1 out of every 4 people over the age of 75, and 1 out of 3 people over 80.
Presently, there are 35 million cases of Alzheimer's Disease worldwide. This number is expected to increase to 115.4 million by 2050.
ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease
The ADDF is very pleased that the FDA has approved Amyvid™, the first diagnostic test for Alzheimer’s disease. This approval marks an important milestone for early detection, diagnosis, treatment and patient care of Alzheimer’s disease and other cognitive disorders.
To view the full announcement, please click here.
6th Annual Connoisseur’s Dinner, “To Live is to Think” will be held on April 26, 2012 at Sotheby’s in New York City to benefit the Alzheimer’s Drug Discovery Foundation.
This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias.
The 2nd Annual Great Ladies Luncheon and Fashion Show will be held on May 2, 2012 at The Ritz-Carlton, Washington DC, to benefit the Alzheimer’s Drug Discovery Foundation.